Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome?

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages

  Cornec, Divi ^a,b   Costa, Sebastian ^c   Devauchelle Pensec, Valérie ^a,b   Chiche, Laurent ^d   Saraux, Alain ^a,b   Pers, Jacques Olivier ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b Universite de Brest   (France)

^c CHU MORVAN   (France)

^d Européen Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

B LYMPHOCYTE; DIAGNOSTIC VALUE; DISEASE DURATION; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; PREDICTIVE VALUE; PRIORITY JOURNAL; SALIVARY GLAND SCINTISCANNING; SHORT SURVEY; SJOEGREN SYNDROME; TREATMENT RESPONSE; SALIVARY GLAND;

B-LYMPHOCYTES; HUMANS; RITUXIMAB; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 84960157603     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209300     Document Type: Short Survey

References (18)

1. Delli K, Haacke EA, Kroese FGM, et al. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann Rheum Dis 2016; Published Online First: 12 Jan 2016. doi.org/10.1136/annrheumdis- 2015-208304.
2. Cornec D, Costa S, Devauchelle-Pensec V, et al. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome. J Autoimmun 2016;67:102-10.
3. Guellec D, Cornec D, Jousse-Joulin S, et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren's syndrome: a systematic review. Autoimmun Rev 2013;12:416-20.
4. Fisher BA, Brown RM, Bowman SJ, et al. A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker. Ann Rheum Dis 2015;74:1645-50.
5. Seror R, Nocturne G, Lazure T, et al. Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study. Arthritis Res Ther 2015;17:241.
6. Cornec D, Jamin C, Pers JO. Sjögren's syndrome: where do we stand, and where shall we go?. J Autoimmun 2014;51:109-14.
7. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximabA randomized trial. Ann Intern Med 2014;160:233-42.
8. Brown S, Coy NN, Pitzalis C, et al. The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjogren's Syndrome. BMC Musculoskelet Disord 2014;15:21.
9. Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, et al. Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sjögren's syndrome. BMC Musculoskelet Disord 2015;67:1623-8.
10. Cornec D, Devauchelle-Pensec V, Mariette X, et al. Development of the Sjögren's syndrome responder index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology 2015;54:1699-708.
11. Devauchelle-Pensec V, Gottenberg J-E, Jousse-Joulin S, et al. Which and how many patients should be included in randomised controlled trials to demonstrate the efficacy of biologics in primary Sjögren's syndrome?. PLoS ONE 2015;10:e0133907.
12. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
13. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 2016;75:382-9.
14. Pijpe J, Kalk WWI, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2007;46:335-41.
15. Costa S, Quintin-Roué I, Lesourd A, et al. Reliability of histopathological salivary gland biopsy assessment in Sjögren's syndrome: a multicentre cohort study. Rheumatology (Oxford) 2015;54:1056-64.
16. Costa S, Schutz S, Cornec D, et al. B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: development and validation of a pixel-based digital procedure. Arthritis Res Ther 2016;18:21.
17. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun 2010;34:400-7.
18. Pollard RPE, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis 2013;72:146-8.